Enfortumab Vedotin in Advanced Urothelial Carcinoma. Reply.
Daniel P Petrylak, Thomas Powles, Jonathan E Rosenberg
Author Information
- Daniel P Petrylak: Yale Cancer Center, New Haven, CT daniel.petrylak@yale.edu.
- Thomas Powles: Barts Cancer Centre, London, United Kingdom.
- Jonathan E Rosenberg: Memorial Sloan Kettering Cancer Center, New York, NY.
No abstract text available.
Antibodies, Monoclonal
Carcinoma, Transitional Cell
Humans
Urinary Bladder Neoplasms
Urologic Neoplasms
Antibodies, Monoclonal
enfortumab vedotin
